ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

SoftBank founder Masayoshi Son tells Nvidia CEO Jensen Huang that he wants to "bring AI intentions into robotics" so the ...

A Dutch appeals court on Tuesday overturned a landmark ruling that ordered energy company Shell to cut its carbon emissions ...

AstraZeneca has invested heavily in China, making the investigations into its business there a concern, but its largest ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company transforming care through the power of portable, ...

AstraZeneca’s corporate headquarters were chosen to be in London, United Kingdom, while its R&D headquarters were to be in Sweden, with major centres of excellence in the UK and USA.

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...